Sadaf Aghevlian
Toronto, ON, Canada
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Formulation of a kit under Good Manufacturing Practices (GMP) for preparing [111In]In-BnDTPA-trastuzumab-NLS injection: a theranostic agent for imaging and Meitner-Auger Electron (MAE) radioimmunotherapy of HER2-positive breast cancer.
Journal: EJNMMI radiopharmacy and chemistry
Published: November 29, 2022
Pre-clinical evaluation of immunoPET imaging using agonist CD40 monoclonal antibody in pancreatic tumor-bearing mice.
Journal: Nuclear medicine and biology
Published: January 17, 2021
Radioimmunotherapy of PANC-1 human pancreatic cancer xenografts in NOD/SCID or NRG mice with Panitumumab labeled with Auger electron emitting, 111In or β-particle emitting, 177Lu.
Journal: EJNMMI radiopharmacy and chemistry
Published: August 04, 2020
Positron emission tomography imaging of novel AAV capsids maps rapid brain accumulation.
Journal: Nature communications
Published: August 31, 2019
MicroSPECT/CT Imaging of Cell-Line and Patient-Derived EGFR-Positive Tumor Xenografts in Mice with Panitumumab Fab Modified with Hexahistidine Peptides To Enable Labeling with 99mTc(I) Tricarbonyl Complex.
Journal: Molecular pharmaceutics
Published: June 27, 2019
Radioimmunotherapy of PANC-1 Human Pancreatic Cancer Xenografts in NRG Mice with Panitumumab Modified with Metal-Chelating Polymers Complexed to 177Lu.
Journal: Molecular pharmaceutics
Published: December 28, 2018
Panitumumab Modified with Metal-Chelating Polymers (MCP) Complexed to 111In and 177Lu-An EGFR-Targeted Theranostic for Pancreatic Cancer.
Journal: Molecular pharmaceutics
Published: January 10, 2018
Radioimmunotherapy of cancer with high linear energy transfer (LET) radiation delivered by radionuclides emitting α-particles or Auger electrons.
Journal: Advanced drug delivery reviews
Published: October 12, 2015
Showing 1-8 of 8
Last Updated: 09/26/2026